Edge Therapeutics Elects Robert J. Spiegel, MD To Board of Directors

  Edge Therapeutics Elects Robert J. Spiegel, MD To Board of Directors

           Former Schering-Plough Chief Medical Officer Joins Board

Business Wire

NEW PROVIDENCE, N.J. -- September 10, 2013

Edge Therapeutics announced today the election of Robert Spiegel, M.D., FACP,
to the Company's Board of Directors.

Dr. Spiegel spent over 25 years at Schering-Plough where he was deeply
involved in clinical development culminating with his position as Chief
Medical Officer. Dr. Spiegel retired in 2009 as Chief Medical Officer and
Senior Vice President of the Schering-Plough Research Institute, the
pharmaceutical research arm of the Schering-Plough Corporation. While at
Schering-Plough, Dr. Spiegel was involved in the filing of over 30 New Drug
Applications and interacted with regulatory authorities in the U.S. and
globally on a regular basis, serving on the executive committees overseeing
all research projects and drug licensing activities. Dr. Spiegel joined
Schering-Plough in 1983 as Director, Clinical Research, progressing through
clinical operations as Vice President of Clinical Research, Senior Vice
President of Worldwide Clinical Research and then becoming Chief Medical
Officer in 1998. He received his undergraduate degree, cum laude, from Yale
University and his medical degree from the University of Pennsylvania. Dr.
Spiegel has served on the Boards of Directors of a number of companies
including: Geron Corporation, Talon Therapeutics, Capstone Therapeutics, and
Clavis Pharma ASA. He is an Associate Professor at Weill Cornell Medical
College and serves on the Board of Directors of Cancer Care, Inc.
Additionally, he is an Advisor at Warburg Pincus.

"We are honored that Bob is joining our board and sharing his wealth of
clinical development experience and his knowledge of regulatory authorities
worldwide," said Brian Leuthner, President and CEO of Edge. "He will prove to
be a tremendous asset as the Company advances its strategy to become a
successful international hospital-focused drug company."

Dr. Sol Barer, Edge Therapeutics Board Chairman noted: "With the addition of
Bob to the Board, we acquire significant clinical and regulatory expertise
from a person who shares common values that focus on the patient and the
development of therapies for life threatening diseases."

"Edge presents an exciting opportunity to develop potential breakthrough
therapies for treating brain hemorrhages and other debilitating critical care
conditions," said Dr. Spiegel. "I look forward to working with the Company's
board and management team during this exciting time of growth for Edge
Therapeutics and to help bring new treatment options to these critical patient
populations."

About Edge Therapeutics

Edge Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company
focused on developing and commercializing life-saving hospital products that
improve patient outcome by addressing acute, fatal or debilitating conditions
after brain hemorrhage that have no current effective treatment. Edge uses its
novel site-specific and sustained-release microparticle technology platform to
deliver drugs to the brain to prevent complications of subarachnoid
hemorrhage, subdural hematoma and intracerebral hemorrhage, all of which
currently have no effective therapies. The Company’s patent-protected
bio-absorbable microparticle formulations release drugs locally and
consistently at therapeutic concentrations in the brain, with the objective of
maximizing therapeutic activity and avoiding treatment-limiting systemic side
effects seen with current treatments. Currently, oral- or IV-administered
therapies are employed in suboptimal concentrations due to the generation of
systemic side effects. Edge’s lead product candidates, EG-1962 (nimodipine
microparticles) and EG-1964, are being developed to prevent various delayed
complications after brain hemorrhage. EG-1962 is a proprietary microparticle
formulation of the calcium channel blocker nimodipine, while EG-1964 delivers
a hemostatic agent. For more information on Edge Therapeutics, Inc., please
visit: www.edgetherapeutics.com.

Contact:

Edge Therapeutics, Inc.
Brian A. Leuthner, 800-208-EDGE
President & CEO
 
Press spacebar to pause and continue. Press esc to stop.